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Although associations have been reported between antidepressant use and risk of breast cancer, the findings have been inconsistent.
We conducted a population-based case–control study among women enrolled in Group Health Cooperative (GHC), a health
maintenance organization in Washington State. Women with a first primary breast cancer diagnosed between 1990 and 2001 were
identified (N¼2904) and five controls were selected for each case (N¼14396). Information on antidepressant use was ascertained
through the GHC pharmacy database and on breast cancer risk factors and screening mammograms from GHC records. Prior to one
year before diagnosis of breast cancer, about 20% of cases and controls had used tricyclic antidepressants (adjusted odds ratio¼1.06,
95% CI 0.94–1.19) and 6% of each group had used selective serotonin reuptake inhibitors (OR¼0.98, 95% CI 0.80–1.18). There
also were no differences between cases and controls with regard to the number of prescriptions filled or the timing of use. Taken as a
whole, the results from this and other studies to date do not indicate an altered risk of breast cancer associated with the use of
antidepressants overall, by class, or for individual antidepressants.
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Antidepressant use has increased steadily (Stafford et al,2 0 0 1 ;
Pirraglia et al,2 0 0 3 ;M e i j e ret al, 2004) since the introduction of
selective serotonin reuptake inhibitors (SSRIs) in the late 1980s, with
use reported by 10–20% of women in recent studies (Moorman
et al, 2003; Steingart et al, 2003; Chien et al,2 0 0 5 ) ,t h o u g ha c t u a lu s e
is likely to be higher due to underreporting (Boudreau et al, 2004).
Antidepressants may affect the risk of breast cancer through the
influence of prolactin, of which elevated levels have been observed
with use of SSRIs, tricyclic antidepressants, and other psychotropic
drugs (Amsterdam et al, 1997; Cowen and Sargent, 1997; Emiliano
and Fudge, 2004). Higher prolactin levels have been associated with
an increased risk of postmenopausal breast cancer (Hankinson
et al, 1999; Tworoger et al, 2004). However, the results of several
studies of a possible association between antidepressant use and
breast cancer risk have been inconsistent (see Discussion section).
To assess more completely the relation of breast cancer with
antidepressant use, we conducted a large case control study using
both computerized pharmacy records as well as records of
reproductive history, family history of breast cancer, and other
breast cancer risk factors. Breast cancer cases diagnosed during
1990–2001 were included, which allowed examination of newer
SSRIs as well as tricyclic antidepressants.
METHODS
All study subjects were enrollees of Group Health Cooperative
(GHC), a health maintenance organization with over 500000
members in western Washington State. Women with a new
diagnosis of invasive or in situ breast cancer diagnosed between
1990 and 2001 were identified by routine linkage between the GHC
enrollment file and the Seattle-Puget Sound Surveillance, Epide-
mology, and End-Results SEER (2005). Five controls were selected
for each case matched on age, calendar year, and length of GHC
membership, with the diagnosis date of the case assigned to each
matched control as the reference date. To ensure more complete
pharmacy records, we restricted cases and controls to women
continuously enrolled at GHC for at least 4 years. We identified
2904 eligible cases age 30–79 when diagnosed with a first primary
invasive or in situ breast cancer and 14396 eligible controls.
Since 1977, the GHC pharmacy database has included a record
for all prescriptions dispensed to GHC enrollees. Each pharmacy
record includes a patient identifier, the drug type and dose, date
dispensed, quantity dispensed, and dosing instructions. Measures
of antidepressant exposure included all prescriptions from the
GHC enrollment start date up to 1 year prior to the reference date,
with the exception of time since last use, which also included
prescriptions filled in the year before the reference date. To
Received 2 December 2005; revised 27 January 2006; accepted 27
January 2006; published online 7 March 2006
*Correspondence: Dr D Fulton-Kehoe, Department of Environmental
and Occupational Health Sciences, University of Washington, School of
Public Health and Community Medicine, Seattle, WA, USA;
E-mail: debfk@u.washington.edu
British Journal of Cancer (2006) 94, 1071–1078
& 2006 Cancer Research UK All rights reserved 0007– 0920/06 $30.00
www.bjcancer.com
E
p
i
d
e
m
i
o
l
o
g
yprovide some assurance that a prescribed drug was actually taken,
we classified women as antidepressant users if they filled at least
two prescriptions in a 6-month interval. We used number of
prescriptions filled as a measure of duration of use, with a typical
prescription filled for 1 month.
We examined antidepressant use overall, individual antidepres-
sant medications, and four classes of antidepressants including
SSRIs, tricyclics, monoamine oxidase inhibitors (MAOIs), and
atypical antidepressants. The SSRI category included paroxetine,
fluoxetine, sertraline, fluvoxamine, and citalopram. Tricyclic
antidepressants included amitriptyline, doxepin, imipramine,
desipramine, nortriptyline, protriptyline, amoxapine, trimipra-
mine, and clomipramine. The MAOIs included phenelzine and
tranylcypromine. Bupropion, mirtazapine, nefazodone, venlafaxine,
maprotiline (a tetracyclic antidepressant), and trazodone were
classified as ‘atypical’ antidepressants.
Information on breast cancer risk factors and mammography
history were obtained from the GHC Breast Cancer Screening
Program (BCSP) databases (Taplin et al, 1990). As part of the
Breast Cancer Screening Program, self-administered question-
naires are first sent to all GHC women when they turn 40 (or enroll
in GHC, whichever is later). Of eligible women, approximately
85–90% enroll in the BCSP and complete the initial questionnaire.
The questionnaire includes information on clinical breast exams,
previous mammograms, menopausal status, use of menopausal
hormone replacement therapy, age at first birth, previous biopsies,
family history of breast cancer, height, weight, education, and race.
Selected questions from the BCSP questionnaire are updated at
each screening visit. GHC also maintains databases of mammo-
grams performed at GHC with dates of each mammogram,
indications for examination (screening or diagnostic), type of
evaluation (standard screening or diagnostic), results, and
recommendations. Based on these records, we determined whether
a study participant had had a screening mammogram in the 2
years prior to her diagnosis or reference date.
Unconditional logistic regression was used to compute odds
ratios (as an estimate of relative risk) and 95% CI for duration and
type of antidepressant use in relation to risk of breast cancer. All
models included the matching factors (age at reference date, length
of GHC membership, and reference year) as continuous variables.
Family history of breast cancer, use and duration of HRT, body
mass index, parity/age at first birth, and mammographic screening
in the 2 years before reference date were determined to be potential
confounders based on their associations with both exposure and
disease. In addition to the matching factors, these factors were
included in all multivariate models.
Our primary analyses included all women with invasive breast
cancer and controls. Additional analyses examined ductal and
lobular cases separately. We also conducted analyses separately of
women with oestrogen receptor (ER) positive and ER negative
tumours, based on routinely collected information from SEER.
Polytomous regression models were used when cases were
classified based on histology or ER status, which resulted in
multiple case groups. To ensure more complete exposure data,
some analyses were restricted to the subgroup of women enrolled
in GHC for at least 10 years (over 70% of eligible subjects in this
study). Cases with in situ disease were examined separately due to
differences in the natural history (Bodian, 1993; Jensen and Page,
2003) and in some risk factors (Weiss et al, 1996; Trentham-Dietz
et al, 2000; Moorman et al, 2003) between invasive and in situ
disease.
RESULTS
Of the 2904 eligible cases, 2449 had invasive breast cancer and 455
had in situ carcinoma. Of the cases with invasive disease, 72% were
ductal, 14% lobular or mixed lobular and ductal, and 14% were
other histologies. Compared to controls, women with invasive
breast cancer were more likely to report a family history of breast
cancer, to be nulliparous, and to be at least 30 years old at first
birth (Table 1). A higher percent of cases reported ever use of HRT
and longer use of HRT. Women with invasive disease were slightly
more likely to be overweight or obese than controls. The
percentage of subjects with a screening mammogram within 2
years of the reference date was higher for invasive cases (71%) than
for controls (58%) and cases were more likely to report a previous
breast biopsy than controls.
Overall, 34% of women had filled at least 1 prescription for
antidepressants up to 1 year before the diagnosis or reference date.
About 24% had filled at least 2 antidepressant prescriptions within
6 months and were considered antidepressant users for this study.
About 20% had filled at least 2 prescriptions for tricyclic
antidepressants. For SSRIs, 6% had filled at least two prescriptions
within 6 months and about 6% filled at least two prescriptions for
atypical antidepressants. For each antidepressant class, women
filled a median of 10 prescriptions.
Among controls, women who used antidepressants were more
likely to report use of HRT than nonusers and had a longer
duration of use than women who had not used antidepressants
(Table 2). A higher percentage of women who used antidepressants
were classified as obese than those who did not use antidepres-
sants. Antidepressant users were also more likely to have had a
screening mammogram within 2 years before the reference date
and had been enrolled at GHC for a longer time than nonusers.
Women who were older, had a younger age at menarche, a first
birth before 20 years of age, or were white were more likely to use
antidepressants, although these differences were relatively small.
When only adjusted for matching factors, the odds ratio for ever
use of antidepressants was slightly elevated (OR¼1.11 95% CI
1.00–1.22, P¼0.048) (Table 3). After adjusting for potential
confounding variables the OR was 1.04 (95% CI¼0.94–1.16). Risk
did not increase with increasing number of antidepressant
prescriptions filled. The odds ratio for tricyclic use was slightly
elevated when adjusted only for matching factors (OR¼1.12, 95%
CI 1.00–1.24), but not after additional adjustment (OR¼1.06, 95%
CI 0.94–1.19). The risk was not elevated with a greater number
of tricyclic prescriptions filled. Ever use of SSRIs also was not
associated with breast cancer risk (adjusted OR¼0.98, 95% CI
0.80–1.18), nor was receipt of a relatively larger number of
prescriptions. Use of atypical antidepressants was not associated
with an increased risk of breast cancer.
In the analyses of the three most common tricyclic medications
(Table 4), there was no association with doxepin or imipramine,
but the odds ratios were somewhat elevated for amitriptyline.
When accounting only for the matching factors, the odds ratio
for ever use of amitriptyline was 1.27 (95% CI 1.10–1.47). The
odds ratio was somewhat attenuated, but still slightly elevated
(OR¼1.21, 95% CI 1.03–1.41) after adjusting for potential
confounding factors. No elevated risks were observed for the
three most common SSRIs (fluoxetine, paroxetine, or sertraline) or
with trazodone, the most common atypical antidepressant.
No patterns of increased risk were seen with time since first use
or time since last use of tricyclics or SSRIs (data not shown).
In analyses by ER status, no associations were seen between
antidepressant use overall, number of antidepressant prescrip-
tions, SSRI use, number of SSRI prescriptions, tricyclic use, or
number of tricyclic prescriptions with either ERþ or ER  breast
cancer (Table 5). With the possible exception of amitriptyline,
individual antidepressants were not associated with either ERþ or
ER  breast cancer. In fully adjusted models for ERþ breast
cancer, the OR for ever use of amitriptyline was 1.22 (95% CI 1.02–
1.45). For 2–10 prescriptions of amitriptyline the OR was 1.19
(95% CI 0.95–1.48) and for 11 or more prescriptions the OR was
1.27 (95% CI 0.96–1.66). No associations were observed with other
individual antidepressant medications (data not shown).
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Cases (N¼2449) Controls (N¼14396)
n % n %
Age at diagnosis/reference date
30–39 92 3.8 507 3.5
40–49 461 18.8 2878 20.0
50–59 611 25.0 3554 24.7
60–69 618 25.2 3646 25.3
70+ 667 27.2 3811 26.5
Length of enrollment
4–9 642 26.2 3781 26.3
10–19 1007 41.1 5900 41.0
20+ years 800 32.7 4715 32.8
First degree family history of breast cancer
Yes 452 20.6 1697 13.5
No 1746 79.4 10833 86.5
Missing 251 (10.3) 1866 (13.0)
Age at menarche
p10 141 6.0 740 5.6
11–14 1936 83.0 10879 82.5
15+ 256 11.0 1566 11.9
Missing 116 (4.7) 1211 (8.4)
Parous
Yes 1910 85.9 11037 87.6
No 314 14.1 1568 12.4
Missing 225 (9.2) 1791 (12.4)
Age at first birth (among parous women)
o20 374 19.6 2174 19.7
20–24 816 42.7 4804 43.5
25–29 443 23.2 2709 24.6
30–34 218 11.4 970 8.8
35+ 58 3.0 377 3.4
Missing 1 (0.05) 4 (0.04)
Use of birth control pills
Yes 1131 53.8 6301 52.0
No 973 49.7 5821 48.0
Missing 345 (14.1) 2274 (15.8)
Ever use of HRT
Yes 1095 50.3 5352 43.8
No 1083 49.7 6858 56.3
Missing 271 (11.1) 2186 (15.2)
Duration of use of HRT
X5 years 632 29.0 2901 23.8
o 5 years 443 20.3 2348 19.2
Duration unknown 20 0.9 103 0.8
None 1083 49.7 6858 56.2
Missing 271 (11.1) 2186 (15.2)
Body mass index
Normal (o25) 1005 46.0 6101 49.7
Overweight (25–29.9) 665 30.4 3536 28.8
Obese (30+) 516 23.6 2631 21.5
Missing 263 (10.7) 2128 (14.8)
Race
White 1859 90.8 9768 89.1
Asian 87 4.3 568 5.2
Black 57 2.8 351 3.2
Multi/other 44 2.2 275 2.5
Missing 402 (16.4) 3434 (23.9)
Education
Less than high school 143 6.7 792 7.2
High school graduate 499 23.3 2627 23.8
Some post secondary 736 34.3 3851 34.9
College graduate 350 16.3 1687 15.3
Advanced degree/some graduate school 418 19.5 2094 19.0
Missing 303 (12.4) 3345 (23.2)
Previous biopsy
Yes 574 25.9 2156 17.2
No 1640 74.1 10406 82.8
Missing 235 (9.6) 1834 (12.7)
At least 1 screening mammogram within 2 years prior to reference date
Yes 1728 70.6 8370 58.1
No 721 29.4 6026 41.9
Antidepressants and breast cancer
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Antidepressant users (N¼3426) Nonusers (N¼10970)
n % n %
Age at reference date
30–39 70 2.0 437 4.0
40–49 635 18.5 2243 20.5
50–59 910 26.6 2644 24.1
60–69 845 24.7 2801 25.5
70+ 966 28.2 2845 25.9
Length of enrollment
4–9 745 21.8 3036 27.7
10–19 1422 41.5 4478 40.8
20+ years 1259 36.8 3456 31.5
First degree family history of breast cancer
Yes 487 15.6 1210 12.9
No 2638 84.4 8195 87.1
Age at menarche
p10 218 6.8 522 5.2
11–14 2653 82.2 8226 82.6
15+ 358 11.1 1208 12.1
Parous
Yes 2759 87.6 8278 87.5
No 389 12.4 1179 12.5
Age at first birth
o20 684 24.8 1490 18.0
20–24 1229 44.6 3575 43.2
25–29 581 21.0 2128 25.7
30–34 189 6.9 781 9.4
35+ 76 2.8 301 3.6
Ever use of HRT
Yes 1638 53.8 3714 40.5
No 1405 46.2 5453 59.5
Duration of use of HRT
X5 years 923 30.8 1978 21.7
o5 years 673 22.4 1675 18.4
None 1405 46.8 5453 59.9
Body mass index
Normal (o25) 1359 44.2 4742 51.6
Overweight (25–29.9) 855 27.8 2681 29.2
Obese (30+) 861 28.0 1770 19.3
Race
White 2502 91.3 7266 88.4
Asian 74 2.7 494 6.0
Black 84 3.1 267 3.3
Multi/other 81 3.0 194 2.4
Education
Less than high school 221 8.0 571 6.9
High school graduate 683 24.6 1944 23.5
Some post secondary 1004 36.1 2847 34.4
College graduate 398 14.3 1289 15.6
Advanced degree/some graduate school 473 17.0 1621 19.6
Previous biopsy
Yes 592 18.9 1564 16.6
No 2547 81.1 7859 83.4
At least 1 screening mammogram within 2 years prior to reference date
Yes 2175 63.5 6195 56.5
No 1251 36.5 4775 43.5
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shown), the odds ratios for the highest category of antidepressant
use (OR¼1.31, 95% CI 1.02–1.68) and the highest category of
tricyclic use (OR¼1.31, 95% CI 1.00–1.88) were somewhat
elevated after adjusting for potential confounders. Risk was not
elevated in any of the other categories of use, with no indication of
a dose–response trend. No associations were seen between risk of
ductal carcinoma and use of SSRIs or atypical antidepressants.
Antidepressant use was not associated with invasive lobular
carcinoma.
When analyses were restricted to women enrolled in GHC for at
least 10 years, risks did not differ for antidepressants overall or any
class of antidepressants (data not shown). Neither any use of
antidepressants overall nor use of a particular class of antidepres-
sants was associated with an increased risk of carcinoma in situ
(data not shown).
DISCUSSION
With few exceptions, no increased risks were observed between
antidepressant use and risk of invasive breast cancer. After
adjustment for potential confounding factors no associations were
seen between risk of breast cancer and antidepressants overall,
SSRIs, tricyclics, or atypical antidepressants. No increased risk was
observed with time since first or last use of any class of
antidepressants. When individual antidepressants were examined,
only amitriptyline exhibited a possible, albeit weak, association
(OR¼1.21, 95% CI 1.03–1.41). Risks were not elevated for any
other individual medications.
Similar to our study, most prior studies have found little or no
association with ever use of antidepressants (all classes combined)
(Cotterchio et al, 2000; Wang et al, 2001; Moorman et al, 2003;
Steingart et al, 2003; Chien et al, 2005), with increasing duration of
use (Cotterchio et al, 2000; Wang et al, 2001; Moorman et al, 2003;
Steingart et al, 2003; Chien et al, 2005), or with time since first or
last use (Steingart et al, 2003; Chien et al, 2005).
For use of tricyclic antidepressants, no increased risks were seen
in most studies for current (Chien et al, 2005; Gonzalez-Perez and
Garcia Rodriguez, 2005) or ever use (Kelly et al, 1999; Cotterchio
et al, 2000; Wang et al, 2001; Sharpe et al, 2002; Moorman et al,
2003; Steingart et al, 2003; Chien et al, 2005). In the present study,
there was a weak positive association when adjusted only for
matching factors and this was attenuated when adjusted for
additional potential confounders. Longer duration of tricyclic use
was associated with an increased risk of breast cancer (OR¼2.1,
95% CI 0.9–5.0) in one study (Cotterchio et al, 2000), but not
in others (Moorman et al, 2003; Gonzalez-Perez and Garcia
Rodriguez, 2005), including the present study, although cutpoints
for the highest category of use have varied. Although we found a
slightly increased risk with use of amitriptyline, other studies that
examined individual tricyclic medications observed no increased
risks associated with use of this drug (Kelly et al, 1999; Cotterchio
et al, 2000; Wang et al, 2001; Steingart et al, 2003). Sharpe et al
(2002) reported an elevated risk of breast cancer associated with
the tricyclic drugs classified as ‘genotoxic’ based on Drosophila
wing development (van Schaik and Graf, 1991; van Schaik and
Graf, 1993). In the present study, no increased risk was observed
either with an increasing number of prescriptions or timing of use
of these same potentially genotoxic tricyclic medications (data not
shown). In fact, in contrast to the findings by Sharpe et al,w e
found a slightly elevated risk of breast cancer associated with use
of nongenotoxic tricyclic drugs, which includes the drug amitripty-
line.
Table 3 Antidepressant use among women with invasive breast cancer and controls
Cases
(N¼2449)
Controls
(N¼14396)
Adjusted for matching factors
a
(N¼16845)
Adjusted for potential confounding
factors
b (N¼13872)
Exposure variables nn OR 95% CI OR 95% CI
No antidepressants 1822 10970 1.00 1.00
Antidepressants
Any use 627 3426 1.11 1.00–1.22 1.04 0.94–1.16
2–10 prescriptions 276 1503 1.11 0.97–1.27 1.04 0.90–1.21
11–20 prescriptions 120 627 1.16 0.95–1.42 1.10 0.89–1.38
21–50 prescriptions 126 760 1.01 0.83–1.22 0.94 0.76–1.16
51+ prescriptions 105 536 1.19 0.96–1.48 1.12 0.89–1.41
Tricyclics
Any use 527 2850 1.12 1.00–1.24 1.06 0.94–1.19
2–10 prescriptions 273 1484 1.11 0.97–1.28 1.05 0.90–1.22
11–20 prescriptions 94 490 1.16 0.92–1.45 1.13 0.89–1.44
21–50 prescriptions 94 557 1.02 0.82–1.28 0.96 0.76–1.23
51+ prescriptions 66 319 1.25 0.96–1.64 1.16 0.86–1.55
SSRIs
Any use 154 911 1.04 0.86–1.24 0.98 0.80–1.18
2–10 prescriptions 78 461 1.03 0.81–1.32 0.97 0.74–1.26
11–20 prescriptions 35 203 1.06 0.73–1.52 0.90 0.60–1.33
21+ prescriptions 41 247 1.02 0.73–1.44 1.04 0.73–1.48
Atypical
Any use 150 876 1.04 0.87–1.25 0.95 0.78–1.16
2–10 prescriptions 90 535 1.02 0.81–1.29 0.93 0.72–1.16
11–20 prescriptions 23 135 1.04 0.99–1.92 1.10 0.68–1.73
21–50 prescriptions 24 142 1.03 0.66–1.59 0.82 0.50–1.34
51+ prescriptions 13 64 1.25 0.68–2.27 1.13 0.60–2.13
aAdjusted for age, length of enrollment, and calendar year.
bAdjusted for age, length of enrollment, calendar year, family history of breast cancer, parity/age at first birth, duration
of HRT use, body mass index, and history of screening mammogram in 2 years prior to reference date.
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et al, 2001; Moorman et al, 2003; Coogan et al, 2005; Gonzalez-
Perez and Garcia Rodriguez, 2005) have not found an association
between ever use of SSRIs and risk of breast cancer, but one
reported a slight increased risk (OR¼1.32, 95% CI 0.97–1.80)
(Steingart et al, 2003). Although recent use of SSRIs was associated
with an increased risk of breast cancer in one study (Kelly et al,
1999), our study and others (Chien et al, 2005; Gonzalez-Perez and
Garcia Rodriguez, 2005) that examined timing of use did not find
a similar association. Duration of SSRI use has been assessed in
this and other studies (Kelly et al, 1999; Cotterchio et al, 2000;
Moorman et al, 2003; Chien et al, 2005; Coogan et al, 2005;
Gonzalez-Perez and Garcia Rodriguez, 2005). One reported a
doubling of the risk (OR¼2.2, 95%CI¼0.8–6.3) with duration
of use longer than 3 years (Moorman et al, 2003), but others have
not observed an increased risk with increasing duration of use,
although few women had used SSRIs for more than 2–3 years.
Individual SSRI medications have been associated with an
increased risk of breast cancer in two previous studies (Cotterchio
et al, 2000; Steingart et al, 2003), but not in others (Chien et al,
2005; Coogan et al, 2005; Gonzalez-Perez and Garcia Rodriguez,
2005; Haque et al, 2005) including our current study. Although one
study reported an elevated odds ratio associated with use of
sertraline (OR¼1.45, 95% CI 0.88–2.40) (Steingart et al, 2003), in
our study and in others (Cotterchio et al, 2000; Coogan et al, 2005)
the risk was not increased. The risk associated with paroxetine
use has been substantially (OR¼7.2, 95% CI 0.9–58.3) (Cotterchio
et al, 2000) and moderately (OR¼1.45, 95% CI 0.88–2.40)
(Steingart et al, 2003) elevated in two studies, but not in ours or
others (Chien et al, 2005; Coogan et al, 2005; Gonzalez-Perez
and Garcia Rodriguez, 2005; Haque et al, 2005). We did not find
an association with ever use of paroxetine (OR 1.00) or with
increasing number of paroxetine prescriptions filled (OR 1.15 for
2–10 prescriptions and 0.52 for at least 11 prescriptions).
Atypical antidepressants have not shown an increased risk in
this or other studies (Moorman et al, 2003; Chien et al, 2005).
Trazodone was a commonly used antidepressant in our study
population, but the number of women reporting use of atypical
antidepressants has been quite low in other studies. Some studies
relying on self-report may underestimate trazodone use if other
indications of antidepressant use (such as insomnia) are not
assessed.
The one other study that evaluated whether the risk associated
with antidepressant use varies by ER status reported associations
of antidepressant use with ER  tumors and with PR  tumors. The
strongest association was observed with SSRIs in ERþ/PR  cases
Table 4 Use of specific antidepressant medications among women with invasive breast cancer and controls
Cases Controls
Adjusted for matching factors
a Adjusted for potential confounding factors
b
Exposure variable nn OR 95% CI OR 95% CI
No antidepressants 1822 10970 1.00 1.00
Tricyclics
Amitriptyline
Any use 250 1191 1.27 1.10–1.47 1.21 1.03–1.41
2–10 prescriptions 151 756 1.20 1.00–1.44 1.17 0.97–1.43
11+ prescriptions 99 435 1.38 1.10–1.72 1.26 0.99–1.60
Doxepin
Any use 186 1101 1.01 0.86–1.19 0.95 0.79–1.13
2–10 prescriptions 120 710 1.01 0.83–1.23 0.94 0.75–1.17
11+ prescriptions 66 391 1.01 0.78–1.32 0.96 0.72–1.27
Imipramine
Any use 127 683 1.13 0.93–1.37 1.04 0.84–1.29
2–10 prescriptions 79 444 1.08 0.84–1.38 0.98 0.76–1.28
11+ prescriptions 48 239 1.22 0.89–1.67 1.15 0.82–1.61
SSRIs
Fluoxetine
Any use 114 611 1.07 0.86–1.34 1.00 0.80–1.25
2–10 prescriptions 59 364 0.99 0.75–1.31 0.94 0.69–1.27
11+ prescriptions 55 297 1.14 0.85–1.53 1.07 0.78–1.46
Paroxetine
Any use 41 241 1.05 0.75–1.48 1.00 0.70–1.41
2–10 prescriptions 36 178 1.25 0.87–1.81 1.15 0.79–1.69
11+ prescriptions 5 63 0.49 0.20–1.23 0.52 0.21–1.31
Sertraline
Any use 40 215 1.15 0.82–1.62 1.16 0.81–1.66
2–10 prescriptions 24 129 1.15 0.74–1.78 1.18 0.75–1.86
11+ prescriptions 16 86 1.15 0.67–1.98 1.12 0.64–1.98
Atypical
Trazodone
Any use 141 802 1.07 0.89–1.29 0.96 0.78–1.18
2–10 prescriptions 82 502 0.99 0.78–1.26 0.88 0.68–1.15
11+ prescriptions 59 300 1.20 0.90–1.59 1.09 0.80–1.49
aAdjusted for age, length of enrollment, and calendar year.
bAdjusted for age, length of enrollment, calendar year, family history of breast cancer, parity/age at first birth, duration
of HRT use, body mass index, history of screening mammogram in 2 years prior to reference date.
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y(OR¼2.0, 95% CI 1.1–3.8)(Chien et al, 2005). We did not find an
association between SSRIs, tricyclics, or antidepressant use overall
with either ERþ or ER  breast cancers. In contrast to the earlier
study (Chien et al, 2005), when we examined ER/PR combinations,
risks were not elevated for ERþ/PR  cases (data not shown).
Recently, one study reported that antidepressant users had a
lower risk of breast cancer among women with a family history of
breast cancer and a higher risk in those without a family history
(Chien et al, 2005). Our results do not replicate this interaction
(data not shown).
Much of the prior research examining antidepressants and
breast cancer risk has relied on the self-reported use of
antidepressants (Kelly et al, 1999; Cotterchio et al, 2000; Moorman
et al, 2003; Steingart et al, 2003; Chien et al, 2005), but recall of
prescription drugs varies according to the type of drug, the
frequency of use, time since medication use, and education level
(Saunders et al, 1994; West et al, 1995). Compared to pharmacy
data, antidepressant use is substantially under-reported (Boudreau
et al, 2004). A study comparing self-reported use of antihyperten-
sives, statins, and antidepressants with pharmacy data found
higher agreement for antihypertensives and statins than for
antidepressant medications. Antidepressant use was recalled only
62% of the time within 6 months prior to reference date, compared
to 94% for antihypertensive use (Boudreau et al, 2004). In
addition, recall of names and dose of medication is relatively low
(West et al, 1995) and the percentage missing timing of use is
relatively high (Boudreau et al, 2004).
One strength of this study is the use of the GHC pharmacy
records. Advantages of using administrative pharmacy records
include having information available for all subjects (not only
respondents), no under-reporting of use, no recall bias, and very
complete information on drug name, dose, and timing of use. As
most studies that use pharmacy databases to assess medication
exposure have limited information on potential confounding
factors (Wang et al, 2001; Sharpe et al, 2002; Gonzalez-Perez and
Garcia Rodriguez, 2005; Haque et al, 2005), another important
strength of the current study is the availability of breast cancer risk
factor data.
One potential weakness of this study is the possibility that some
women may have been prescribed antidepressants that were not
included in the GHC pharmacy database. Prescriptions that were
filled prior to the initiation of the pharmacy database in 1977, prior
to enrollment in GHC, or filled out of the GHC system were not
captured in the pharmacy databases. However, the number of
antidepressants prescriptions filled outside the GHC system is
likely to be small because antidepressant prescriptions were
available free or with a small copayment for many GHC members.
Further, others have reported that over 95% of prescriptions for
antidepressants among GHC members are filled at a GHC
pharmacy (Saunders et al, 1994). While we could not identify
antidepressant use prior to GHC membership, we conducted
subset analyses among women with at least 10 years of pharmacy
data to ensure more complete history of antidepressant use. Over
70% of the subjects in this study were enrolled for more than 10
years as of their reference date and the conclusions based on this
restricted sample were unchanged.
Another potential limitation of this study is a relatively short
follow-up time for paroxetine exposure. Paroxetine was on the
Table 5 Antidepressant use among women with invasive breast cancer, by ER status, and controls
ER+ cases ER– cases Controls
ER+ compared to controls
a ER  compared to controls
a
Exposure variables nn n OR 95% CI OR 95% CI
No antidepressants 1307 325 10970 1.00 1.00
Antidepressant
Any use 457 106 3426 1.05 0.93–1.19 1.01 0.79–1.30
2–10 prescriptions 207 45 1503 1.09 0.92–1.29 0.93 0.65–1.33
11–20 prescriptions 95 16 627 1.19 0.94–1.51 0.87 0.50–1.50
21–50 prescriptions 84 25 760 0.85 0.67–1.10 1.05 0.66–1.65
51+ prescriptions 71 20 536 1.04 0.79–1.36 1.39 0.86–2.26
Tricyclic
Any use 386 84 2850 1.07 0.94–1.21 0.95 0.72–1.24
2–10 prescriptions 200 48 1484 0.97 0.68–1.38 1.06 0.90–1.26
11–20 prescriptions 74 12 490 0.92 0.51–1.66 1.19 0.92–1.55
21–50 prescriptions 67 10 557 0.55 0.27–1.13 0.94 0.72–1.25
51+ prescriptions 45 14 319 1.63 0.91–2.90 1.09 0.77–1.60
SSRI
Any use 108 28 911 0.93 0.74–1.16 1.05 0.69–1.60
2–10 prescriptions 55 13 461 0.92 0.68–1.24 1.05 0.59–1.87
11–20 prescriptions 26 7 203 0.95 0.61–1.47 0.87 0.35–2.15
21+ prescriptions 27 8 247 0.93 0.62–1.41 1.21 0.58–2.51
Atypical
Any use 108 31 876 0.92 0.73–1.16 1.15 0.76–1.74
2–10 prescriptions 66 19 535 0.93 0.70–1.23 1.11 0.66–1.86
11–20 prescriptions 17 6 135 1.06 0.62–1.80 1.76 0.76–4.07
21+ prescriptions 25 6 206 0.82 0.52–1.31 0.89 0.36–2.20
Amitriptyline
Any use 186 38 1191 1.22 1.02–1.45 1.09 0.75–1.58
2–10 prescriptions 113 23 756 1.19 0.95–1.48 1.05 0.66–1.67
11+ prescriptions 73 15 435 1.27 0.96–1.66 1.16 0.65–2.06
aAdjusted for age, length of enrollment, calendar year, family history of breast cancer, parity/age at first birth, duration of HRT use, body mass index, and history of screening
mammogram in 2 years prior to reference date.
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ymarket in the United States in 1993, but because it was not a
preferred drug in the GHC formulary, it was not used often within
GHC until 1997. As a result, fewer subjects in this study population
had ever used paroxetine and the duration of use was shorter than
what would be expected in the general population during the same
time period.
Overall, the results from this and other epidemiologic studies do
not provide evidence for an increased risk of breast cancer
associated with the use of antidepressants overall, by class of drug,
or for individual antidepressants. Although a few studies have
reported elevated risks in select analyses, the findings have not
been consistent by class of drug, type of individual drug, or timing
of use. The lack of consistency across studies suggests that any
observed elevated risks could be due to chance. If there were a
causal relationship, breast cancer risk would likely increase with
longer duration of exposure. A few studies have reported elevated
risks in longer-term users of some agents (Cotterchio et al, 2000;
Moorman et al, 2003), but the class has differed. Overall, risk of
breast cancer has not varied in any systematic pattern by timing of
antidepressant use. As SSRIs have only been available in the
relatively recent past, we cannot rule out the possibility of an effect
with longer duration or longer time since first use, but the
accumulating evidence does not suggest an association.
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